Table 3.
Conditional logistic regression analysis for HZ risk in JAKi users compared with bDMARD users
| Univariable (n=671) |
Multivariable model 1* (n=668) |
Multivariable model 2† (n=668) |
Multivariable model 3‡ (n=626) |
Multivariable model 4§ (n=609) |
||||||
| OR (95% CI) | P value | Adjusted OR (95% CI) |
P value | Adjusted OR (95% CI) |
P value | Adjusted OR (95% CI) |
P value | Adjusted OR (95% CI) |
P value | |
| bDMARD use JAKi use |
1.00 (ref) 1.60 (0.88 to 2.90) |
0.124 | 1.00 (ref) 1.35 (0.70 to 2.61) |
0.365 | 1.00 (ref) 1.35 (0.70 to 2.60) |
0.370 | 1.00 (ref) 1.25 (0.63 to 2.47) |
0.518 | 1.00 (ref) 1.25 (0.63 to 2.49) |
0.525 |
*Adjusted for duration of RA, number of previous targeted therapy, oral glucocorticoid use, DAS28-ESR and fatigue VAS.
†Adjusted for methotrexate use in addition to factors included in model 1.
‡Adjusted for BMI and diabetes mellitus in addition to factors included in model 2.
§Adjusted for HAQ-DI and sleep VAS in addition to factors included in model 3.
bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; HZ, herpes zoster; JAKi, Janus kinase inhibitor; ref, reference group.